secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2024-04-01T23:59:59+00:00
Accession:  0001493152-24-012530
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 2.01, 1.01, 9.01, 2.03, 3.03, 5.01, 5.02, 5.03, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

AgeX completes reverse merger with Serina; becomes Serina Therapeutics, trades as SER
--------------------------------------------------------------------------------

- Merger closed March 26, 2024; Serina shares converted at 0.97682654 per AgeX share; 5,913,277 shares issued to Serina stockholders.
- Post-merger ~10.1M shares outstanding (fully diluted excl. warrants); Serina equityholders own ~75%, AgeX legacy ~25%.
- AgeX changed name to Serina Therapeutics, Inc.; ticker changes from AGE to SER, new CUSIP 81751A108.
- Board reconstituted: J. Milton Harris (Chair), Steven Ledger (Interim CEO & Dir), Andrea Park (Interim CFO), Randall Moreadith (CSO).
- AgeX drew additional $2.4M under Juvenescence convertible note; transferred notes and certain assets to UniverXome in exchange for release.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000149315224012530/0001493152-24-012530-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000149315224012530/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-012530

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer